
Last updated: 2026-09-18 16:19:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $1.96, with a market capitalization of $3.23M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $7.05. This page covers its latest market performance, valuation, price trends and company information.
$3.23M | |
$1.95 | |
$1,513.35 | |
$1.58 | |
$1.66 | |
6.31M | |
106.24K | |
-- | |
$7.05 | |
$1.58 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) is currently trading at $1.96 as of 2026-09-18 16:17:00, up 17.77% ($0.30) from the previous close of $1.66
During today's regular trading session, XRTX has traded between $1.58 and $1,513.35, with a trading volume of 6.31M shares. The current price is near the lower end of today's range.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $2.16 to $1.96, representing a decline of 9.41% ($0.20).
The stock traded between $1.58 and $2.52 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 859.51 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 6.9%
XRTX is currently trading at $1.96, placing it 6.9% of the way from its 52-week low of $1.58 to its 52-week high of $7.05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.